Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROR1 | Q01973 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26874208 | 0.80 | PTGDR2 (0.35) | PTGDR2ALDH1A1CNR2CNR1KDM4E | |
| SCHEMBL16018026 | 0.76 | CNR2 (0.40) | PTGDR2MEN1KMT2ACNR2CNR1 | |
| SCHEMBL24204617 | 0.75 | CNR2 (0.37) | PTGDR2CNR2CNR1PTGDR | |
| SCHEMBL16009514 | 0.74 | MAP2K3 (0.40) | MEN1KMT2AALDH1A1CNR2CNR1 | |
| SCHEMBL24346128 | 0.72 | FDPS (0.36) | PTGDR2MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL24204698 | 0.71 | DRD2 (0.42) | PTGDR2 | |
| SCHEMBL16010033 | 0.69 | ALDH1A1 (0.38) | ROR1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL29207265 | 0.69 | ROR1 (0.34) | ROR1ALDH1A1 | |
| SCHEMBL28603871 | 0.69 | TNFRSF1A (0.38) | ROR1MEN1KMT2AHDAC3HDAC4 | |
| SCHEMBL15114736 | 0.68 | TNFRSF1A (0.40) | ROR1MEN1KMT2AALDH1A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | Unilever PLC, a company registered in England and Wales under company no. 41424 of (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | ROR1 725/4885PTGDR2 4453/4885MEN1 4079/4885 |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | ROR1 725/4885PTGDR2 4453/4885MEN1 4079/4885 |
| US-10470986-B2 | Resorcinol compounds for dermatological use | NQO1, RBP4, KEAP1 | ROR1 725/4885PTGDR2 4453/4885MEN1 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.